|Articles|February 9, 2022
- Pharmaceutical Executive-02-01-2022
- Volume 42
- Issue 2
Pharmaceutical Executive, February 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive February 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 3 years ago
As Change Continues, Are You Digitally Fit For the Future?over 3 years ago
Ready for Pharma’s Next Chapterover 3 years ago
The Tech Perspective: Coordinating a Plan of Engagementover 3 years ago
The Importance of Culturally Inclusive and Relevant Marketingover 3 years ago
Messaging Makeoverover 3 years ago
Ethics of Antibioticsover 3 years ago
What’s Up in Biotech These Days? Not Much, Unfortunatelyover 3 years ago
Planning for Second to Market in Orphan Disease Spaceover 3 years ago
AI and Analytics Appear Ready to Surge in Sales and Marketingover 3 years ago
It’s Time for Companies To See Employees as Full-Time PeopleNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
